No Data
No Data
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32
Is It Too Late to Buy Iovance Biotherapeutics Stock?
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Is Maintained at Market Outperform by JMP Securities
JMP Securities Adjusts Price Target on Iovance Biotherapeutics to $23 From $25, Maintains Market Outperform Rating